Literature DB >> 19776699

Additional spirometry criteria predict postoperative complications after coronary artery bypass grafting (CABG) independently of concomitant chronic obstructive pulmonary disease: when is off-pump CABG more beneficial?

Maria K Lizak1, Edward Nash, Michał Zakliczyński, Joanna Sliwka, Piotr Knapik, Marian Zembala.   

Abstract

INTRODUCTION: Concomitant chronic obstructive pulmonary disease (COPD) is associated with an increased rate of post-coronary artery bypass grafting (CABG) complications. The ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) <70%, proposed by the Global Initiative for Chronic Obstructive Lung Disease as a criterion for the diagnosis of COPD, is criticized for not considering physiological, age-related changes in lung function.
OBJECTIVES: The aim of the study was to evaluate which of the additional spirometric parameters, adjusted for age and the distribution of values in the population, represent the best predictors of post-CABG complications and to identify patients who are more likely to benefit from off-pump cardiac bypass (OPCAB) than from CABG. PATIENTS AND METHODS: In the retrospective cohort study, data from a total of 3617 CABG or OPCAB patients were recorded. Patients with COPD, diagnosed prior to admission, were classified according to the spirometry results: group 1 with FEV1/FVC <70%, group 2 with FEV1/FVC below the mean normal value adjusted to age, group 3 with FEV1/FVC below the lower limit of normal (LLN), group 4 with FEV1 <LLN. The control group comprised subjects with no history of COPD. The occurrence of post-CABG complications was analyzed using the chi2 and Mann-Whitney U tests.
RESULTS: FEV1 below LLN predicted a higher incidence of reoperation, readmission to intensive care unit (ICU), sternal wound infection, pulmonary complications, and pulmonary edema after surgery (p <0.05). CABG patients with FEV1 below LLN stayed in the ICU significantly longer than OPCAB patients, and tended to require prolonged mechanical ventilation and more time from operation to discharge.
CONCLUSIONS: FEV1 <LLN is the best prognostic marker for post-CABG complications independently of concomitant COPD. Patients with FEV1 <LLN have better outcomes after OPCAB compared with those post-CABG.

Entities:  

Mesh:

Year:  2009        PMID: 19776699

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  5 in total

1.  Arterial Blood Gas Analysis in Chronic Obstructive Pulmonary Disease Patients Undergoing Coronary Artery Bypass Surgery.

Authors:  Sami İlhan; Rafet Günay; Sevil Özkan; Tolga Sinan Güvenç; Nurgül Yurtsever
Journal:  Turk Thorac J       Date:  2016-07-01

2.  Evaluation of spirometry findings with severity of coronary artery disease in smoker patients undergoing angiography in military hospital during 2019-2020.

Authors:  Milad Kabiri Samani; Seyed Hossein Mosavi; Reza Arefizadeh
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15

3.  Pleural subxyphoid drain confers better pulmonary function and clinical outcomes in chronic obstructive pulmonary disease after off-pump coronary artery bypass grafting: a randomized controlled trial.

Authors:  Solange Guizilini; Marcela Viceconte; Gabriel Tavares da M Esperança; Douglas W Bolzan; Milena Vidotto; Rita Simone L Moreira; Andréia Azevedo Câncio; Walter J Gomes
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

4.  Postoperative outcomes of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass grafting surgery: A meta-analysis.

Authors:  Hui Zhao; Lifang Li; Guang Yang; Jiannan Gong; Lu Ye; Shuyin Zhi; Xulong Zhang; Jianqiang Li
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

5.  Forced expiratory volume in one second predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery: a retrospective cohort study.

Authors:  David A McAllister; Sarah H Wild; John D MacLay; Andrew Robson; David E Newby; William MacNee; J Alastair Innes; Vipin Zamvar; Nicholas L Mills
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.